SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I. Luttichuys who wrote (164)12/5/1996 6:26:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Bennett, Another great day for Idec and the biotechs. At the ASH conference I am going to represent a group of NHL patients that are desperatley in need of C2B8 and need it now. These patients have exhausted most measures of writing their congress representatives and Dr. Kessler of the FDA. In Eric Hecht's latest update he is ownly looking at C2B8/chemo as a frontline treatment over time. I respect his conservatism but the NHL patients that I'm talking with would request C2B8 with its strong efficacy and low side effect profile before the thought of chemo. However he did say he has talked to a few oncologists who say they will use C2B8 with all their patients. Idec's last presentation is on Monday at 11:00 EST so I would expect to see a press release sometime in the afternoon.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News